2.1	Table of Contents of Module 2

Table of Contents : Module 2

Table of Contents : Module 2

Table of Contents : Module 3

Section	Contents	
List of abbreviations used in dossier		
3.1	**Module 3 Table of Contents**	
3.2	**Body of Data**	
3.2.S	**DRUG SUBSTANCE**	
3.2.S.1	**General Information**	
3.2.S.1.1	Nomenclature	
3.2.S.1.2	Structure	
3.2.S.1.3	General Properties	
3.2.S.2	**Manufacture**	
3.2.S.2.1	Manufacturer(s)	
3.2.S.2.2	Description of manufacturing process and process controls	
3.2.S.2.3	Control of materials	
3.2.S.2.4	Controls of critical steps and intermediates	The information contained in this section is disclosed in Restricted Part.
3.2.S.2.5	Process validation and / or evaluation	
3.2.S.2.6	Manufacturing process development	
3.2.S.3	**Characterization**	
3.2.S.3.1	Elucidation of structure and other characteristics	
3.2.S.3.2	Impurities	
3.2.S.4	**Control of Drug Substance**	
3.2.S.4.1	Specification	
3.2.S.4.2	Analytical procedures	
3.2.S.4.3	Validation of analytical procedures	
3.2.S.4.4	Batch Analysis	

Table of Contents : Module 3

Section	Contents
3.2.P.5	**Control of Drug Product**
3.2.P.5.1	Specification(s)
3.2.P.5.2	Analytical Procedures
3.2.P.5.3	Validation of Analytical Procedures
3.2.P.5.4	Batch Analysis
3.2.P.5.5	Characterisation of Impurities
3.2.P.5.6	Justification of Specification(s)
3.2.P.6	**Reference Standards or Materials**
3.2.P.7	**Container Closure System**
3.2.P.8	**Stability**
3.2.P.8.1	Stability Summary and Conclusion
3.2.P.8.2	Post-approval Stability Protocol and Stability Commitment
3.2.P.8.3	Stability Data
3.2.A	**Appendices**
3.2.A.1	Facilities and Equipment
3.2.A.2	Adventitious Agents Safety Evaluation
3.2.A.3	Excipients
3.2.R	**Regional information**